Katsumi Tamura MD, Presenter: Nothing to Disclose

Ikuko Sakata MD, Abstract Co-Author: Nothing to Disclose

Jiro Ishida MD, Abstract Co-Author: Nothing to Disclose

Kyosan Yoshikawa MD, Abstract Co-Author: Nothing to Disclose

Atsushi Kubo MD, Abstract Co-Author: Nothing to Disclose

Shigeru Kosuda MD, Abstract Co-Author: Nothing to Disclose

Kikuo Machida MD, PhD, Abstract Co-Author: Nothing to Disclose

Yoshiyuki Abe MD, PhD, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

The accumulation in the gastrointestinal tract often pesters nuclear medicine physicians with the interpretation as to whether “ normal or not ” because 18F-FDG frequently accumulates not only in the abnormal lesion like malignant tumor but also in the normal stomach and intestines. The purpose of this study is to assess the ability of scopolamine butylbromide that inhibits the periatalsis to reduce physiologic uptakes in the stomach and colon.

We studied 148 people who had a checkup for cancer using PET/CT. All people are less than fifty years old and mean age was 41.3±6.03. We administered an intravenous drip injection of isotonic sodium chloride solution including scopolamine butylbromide of 20mg to 66 people in this study for 30 minutes. The drip was started at five minutes before the injection of 18F-FDG. We categorized the degree of 18F-FDG uptake in the stomach and along the colon into four grades according to the following scale: Grade 0: no visible uptake; Grade 1: lower than in the liver; Grade 2: similar to the liver; Grade 3: higher than in the liver. Also, we measured SUV in the stomach and counted the number of nodular uptakes in the colon that is higher than in the liver.

The mean Grade of stomach in the injection group (1.11±0.75SD) was significantly lower than that in the non-injection group (1.94±0.91) (p<0.0001). Also, the mean Grade of colon in the injection group (0.88±0.83) was significantly lower than that in the non-injection group (1.26±0.91) (p=0.010). The mean SUV of the stomach in the injection group (2.68±0.70) was significantly lower than that in the non-injection group (3.26±0.75). The number of nodular uptakes in the colon in the injection group(0.15±0.40) was lower than that in the non-injection group (0.37±0.96), but the significant difference was not found (p=0.066).

The injection of scopolamine butylbromide is considered to be an effective method to reduce the physiologic uptake in the gastrointestinal tract, especially in the stomach.

The injection of scopolamine butylbromide can reduce the physiologic uptake in the gastrointestinal tract, especially in the stomach.

Tamura, K, Sakata, I, Ishida, J, Yoshikawa, K, Kubo, A, Kosuda, S, Machida, K, Abe, Y, et al, , et al, , FDG-PET/CT Using Scopolamine Butylbromide to Reduce Physiologic Uptakes in the Gastrointestinal Tract.  Radiological Society of North America 2007 Scientific Assembly and Annual Meeting, November 25 - November 30, 2007 ,Chicago IL. http://archive.rsna.org/2007/5003786.html